Certain Equity Shares of Mankind Pharma Limited are subject to a Lock-Up Agreement Ending on 20-MAR-2025.
Published on 20/03/2025 at 04:30
Share
Certain Equity Shares of Mankind Pharma Limited are subject to a Lock-Up Agreement Ending on 20-MAR-2025. These Equity Shares will be under lockup for 90 days starting from 20-DEC-2024 to 20-MAR-2025.
Details:
The Promoters agrees, subject to the exceptions set out below, not to (a) issue, offer, lend, pledge, sell, contract to sell or issue, sell any option or contract to purchase, purchase any option or contract to sell or issue, grant any option, issue right or warrant to purchase any interest in any Equity Shares, lend or otherwise transfer or dispose of, directly or indirectly, any equity shares, or any securities convertible into or exercisable or exchangeable for Equity Share; (b) enter into any swap or other agreement that transfers, directly or indirectly, in whole or in part, any of the economic consequences of ownership of Equity Shares whether any such transaction described in (a) or (b) above is to be settled by delivery of Equity Shares, or such other securities, in cash or otherwise; or (c) publicly announce any intention to enter into any transaction described in (a) or (b) above, for a period from the date hereof up to 90 days after the date of Allotment of Equity Shares without the prior written consent of BRLMs. However, the foregoing restriction shall not be applicable to any transaction required by law or an order of a court of law or a statutory authority.
Mankind Pharma Limited is an India-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans womenâs health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.